Ribbon Biolabs
Edit

Ribbon Biolabs

http://ribbonbiolabs.com/
Last activity: 21.12.2023
Active
Categories: BioTechFinTechLifeTechnologyWebsite
Ribbon Biolabs defines new standards for molecular biology by applying innovative methods for DNA synthesis.
Ribbon Biolabs is a startup company based in Vienna, Austria, developing a new technology to synthesize large volumes of large and/or complex DNA molecules. Our team comprises 5 highly competent scientists of varied expertise and an experienced Project Manager.
Followers
217
Mentions
8
Location: Austria, Vienna
Employees: 11-50
Total raised: $25M
Founded date: 2018

Investors 2

Funding Rounds 1

DateSeriesAmountInvestors
02.02.2022Series A$25M-

Mentions in press and media 8

DateTitleDescription
21.12.2023Hadean Ventures announces oversubscribed final close of Hadean Capital IIHadean Ventures announces oversubscribed final close of Hadean Capital II – a fund dedicated to investments in life science start-ups across Europe Oslo, 21 December 2023. Hadean Ventures announced today the final close of Hadean Capital I...
08.12.2023Ribbon Biolabs appoints Jodi Barrientos Chief Executive OfficerRibbon Biolabs appoints Jodi Barrientos Chief Executive Officer; Founder Harold De Vladar named an advisor and board member. Vienna, Austria, December 6, 2023 – Ribbon Biolabs GmbH, the DNA synthesis company, announced today that its Board...
07.11.2023Life sciences in Austria: Innovation moves mountainsSetting up the startup phase, applying for funding, finding employees and investors, thinking through forms of financing, developing business models, opening up sales markets and so on — a lot of steps are necessary to go from an idea to a ...
04.01.2023Daily AI Roundup: Biggest Machine Learning, Robotic And Automation Updates 4th January 2023This is our AI Daily Roundup today. We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI), Machine Learning, Robotic Process Automation, Fintech, and hu...
03.01.2023Ribbon Biolabs Reaches Key Milestone with Automation of InfiniSynth Platform for Commercial-scale, Unlimited Length DNA SynthesisRibbon Biolabs, the DNA synthesis company, announced the successful implementation of their innovative InfiniSynth platform for the automated assembly of sequence-agnostic and long DNA. Ribbon Biolabs achieved this milestone in collaboratio...
31.01.2022Ribbon Biolabs raises EUR 18 million in its Series A financingVIENNA, AUSTRIA, January 31, 2022 — Ribbon Biolabs, the DNA synthesis company, today announced the successful close of EUR 18 million in its Series A funding round from a consortium of European and US investors led by Hadean Ventures and...
31.01.2022Ribbon Biolabs Raises EUR 18 Million Series A Financing Enabling Commercial Scale Production Facilities and US Expansion for DNA Synthesis TechnologyRibbon Biolabs, the DNA synthesis company, today announced the successful close of EUR 18 million in its Series A funding round from a consortium of European and US investors led by Hadean Ventures and with participation from Lansdowne Part...
31.01.2022Ribbon Biolabs Raises EUR18M in Series A FinancingRibbon Biolabs, a Vienna, Austria-based DNA synthesis company, closed EUR 18m in its Series A funding. The round was led by Hadean Ventures and with participation from Lansdowne Partners, Helicase Venture as well as several undisclosed inve...

Reviews 0

Sign up to leave a review

Sign up Log In